|
Accession Number
|
ADA567468
|
|
Title
|
T Cell Gene Therapy to Eradicate Disseminated Breast Cancers.
|
|
Publication Date
|
May 2012
|
|
Media Count
|
52p
|
|
Personal Author
|
R. P. Junghans
|
|
Abstract
|
There is no cure for metastatic breast cancer, which kills 40,000 American women (and 500 men) each year: all presently available treatments are palliative. Gene therapy techniques are used to introduce chimeric immunoglobulin-T cell receptors (IgTCR) into autologous patient T cells to create designer T cells that redirect the T cell immune system in a new type of immuno-gene therapy against breast cancer. Designer T cells have been created against the carcinoembryonic antigen (CEA) that is prominently present on many metastatic breast tumors (30-60%). This exceeds the fraction that are Her2/neu overexpressing (20-25%), making CEA an even better immune target for attacking breast cancer. Building on a prior study of CEA designer T cells in breast and colon cancer, 2nd generation designer T cells were created by incorporating into the IgTCR a CD28 co-stimulation cassette that was shown to oppose activation-induced cell death (AICD) of the T cells after tumor contact. This advanced generation modification leads to improved designer T cell survival and improved anti-tumor potency in preclinical models. Although the 2nd generation designer T cells produce interleukin 2 (IL2) growth factor on contact with tumor, interleukin 2 (IL2) supplementation is anticipated still to be required for optimal clinical therapeutic effect. However, the CBER/FDA has mandated a Phase I.
|
|
Keywords
|
Breast cancer
Cells(Biology)
Clinical medicine
Colon cancer
Death
Gene therapy
Immunity
Mammary glands
Metastasis
T lymphocytes
|
|
|
Source Agency
|
Non Paid ADAS
|
|
NTIS Subject Category
|
57A - Anatomy
57S - Physiology
57E - Clinical Medicine
|
|
Corporate Author
|
Army Medical Research and Materiel Command (Provisional), Fort Detrick, MD.
|
|
Document Type
|
Technical report
|
|
Title Note
|
Annual rept. 1 May 2011-30 Apr 2012.
|
|
NTIS Issue Number
|
1309
|
|
Contract Number
|
W81XWH-09-1-0039
|
